The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Genomic testing in high-risk smoldering myeloma: advice for community hematologists
Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights the current lack of clear indications for genomics in high-risk smoldering myeloma outside research, but notes that a targeted panel can provide valuable information, particularly for newly diagnosed myeloma. Dr Maura emphasizes the importance of preparing for a future where myeloma diagnosis and smoldering myeloma risk assessment will be based on genomics. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that currently there are no clear indications to do genomics for smoldering myeloma outside of research. We are working with the community to generate such guidelines and identify the right markers and the right technology accessible for the community so you can do a better prognostication for your patients in your clinic. That said, I think a targeted panel most of the time should have good information, maybe not for smoldering, but for new diagnosis myeloma for sure...
I think that currently there are no clear indications to do genomics for smoldering myeloma outside of research. We are working with the community to generate such guidelines and identify the right markers and the right technology accessible for the community so you can do a better prognostication for your patients in your clinic. That said, I think a targeted panel most of the time should have good information, maybe not for smoldering, but for new diagnosis myeloma for sure. And we should ensure people start to work around this because things will change. In a few years, we will have a definition of myeloma that is based on genomics and smoldering will be risk-based on genomics. So better to be prepared now because that’s inevitable.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
